{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T12:30:33Z","timestamp":1746793833523},"reference-count":78,"publisher":"Impact Journals, LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aging"],"DOI":"10.18632\/aging.204766","type":"journal-article","created":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T21:58:12Z","timestamp":1685743092000},"source":"Crossref","is-referenced-by-count":3,"title":["The potential of FCRL genes as targets for cancer treatment: insights from bioinformatics and immunology"],"prefix":"10.18632","author":[{"given":"Xiao","family":"Liang","sequence":"first","affiliation":[{"name":"Department of Anesthesiology, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Du","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuchao","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, Sichuan Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2023,6,2]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023.","volume":"7","author":"Jemal","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"2","doi-asserted-by":"publisher","first-page":"144","DOI":"10.3322\/caac.21706","article-title":"Integrative oncology: Addressing the global challenges of cancer prevention and treatment.","volume":"7","author":"C\u00e1ceres Guido","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"3","doi-asserted-by":"publisher","first-page":"287","DOI":"10.3322\/caac.21714","article-title":"An overview of real-world data sources for oncology and considerations for research.","volume":"7","author":"Meyer","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"4","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1146\/annurev.immunol.25.022106.141541","article-title":"Fc receptor-like molecules.","volume":"2","author":"Davis","year":"2007","journal-title":"Annu Rev Immunol"},{"key":"5","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/82_2010_88","article-title":"Immunoregulatory roles for fc receptor-like molecules.","volume":"35","author":"Cooper","year":"2011","journal-title":"Curr Top Microbiol Immunol"},{"key":"6","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1080\/14728222.2018.1472768","article-title":"Update on Fc receptor-like (FCRL) family: new immunoregulatory players in health and diseases.","volume":"2","author":"Shabani","year":"2018","journal-title":"Expert Opin Ther Targets"},{"key":"7","doi-asserted-by":"publisher","first-page":"575175","DOI":"10.3389\/fimmu.2020.575175","article-title":"Roles for the FCRL6 Immunoreceptor in Tumor Immunology.","volume":"1","author":"Davis","year":"2020","journal-title":"Front Immunol"},{"key":"8","doi-asserted-by":"publisher","first-page":"8509805","DOI":"10.1155\/2020\/8509805","article-title":"Development and Validation of the B Cell-Associated Fc Receptor-like Molecule-Based Prognostic Signature in Skin Cutaneous Melanoma.","volume":"202","author":"Li","year":"2020","journal-title":"Biomed Res Int"},{"key":"9","doi-asserted-by":"publisher","first-page":"882307","DOI":"10.3389\/fgene.2022.882307","article-title":"High Expression of FCRLB Predicts Poor Prognosis in Patients With Colorectal Cancer.","volume":"1","author":"Chen","year":"2022","journal-title":"Front Genet"},{"key":"10","doi-asserted-by":"publisher","first-page":"7518","DOI":"10.4049\/jimmunol.0802230","article-title":"Fc receptor-like 3 protein expressed on IL-2 nonresponsive subset of human regulatory T cells.","volume":"18","author":"Pastan","year":"2009","journal-title":"J Immunol"},{"key":"11","doi-asserted-by":"publisher","first-page":"3639","DOI":"10.4049\/jimmunol.0903943","article-title":"Expression of the autoimmune susceptibility gene FcRL3 on human regulatory T cells is associated with dysfunction and high levels of programmed cell death-1.","volume":"18","author":"McCune","year":"2010","journal-title":"J Immunol"},{"key":"12","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1111\/nyas.12771","article-title":"FCRL regulation in innate-like B cells.","volume":"136","author":"Davis","year":"2015","journal-title":"Ann N Y Acad Sci"},{"key":"13","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling.","volume":"40","author":"Marti","year":"2000","journal-title":"Nature"},{"key":"14","doi-asserted-by":"publisher","first-page":"1177271919882351","DOI":"10.1177\/1177271919882351","article-title":"Fc Receptor-Like 1 as a Promising Target for Immunotherapeutic Interventions of B-Cell-Related Disorders.","volume":"1","author":"Eskandari","year":"2019","journal-title":"Biomark Insights"},{"key":"15","doi-asserted-by":"publisher","first-page":"973881","DOI":"10.3389\/fimmu.2022.973881","article-title":"Why do tumor-infiltrating lymphocytes have variable efficacy in the treatment of solid tumors?","volume":"1","author":"Li","year":"2022","journal-title":"Front Immunol"},{"key":"16","doi-asserted-by":"publisher","first-page":"6027305","DOI":"10.1155\/2017\/6027305","article-title":"Inflammation, Immunity, and Cancer.","volume":"201","author":"Aggarwal","year":"2017","journal-title":"Mediators Inflamm"},{"key":"17","doi-asserted-by":"publisher","first-page":"1018962","DOI":"10.3389\/fimmu.2022.1018962","article-title":"Tumor-infiltrating lymphocytes for treatment of solid tumors: It takes two to tango?","volume":"1","author":"Falak","year":"2022","journal-title":"Front Immunol"},{"key":"18","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1126\/science.1129139","article-title":"Type, density, and location of immune cells within human colorectal tumors predict clinical outcome.","volume":"31","author":"Cugnenc","year":"2006","journal-title":"Science"},{"key":"19","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/978-3-319-07911-0_2","article-title":"Emerging roles for the FCRL family members in lymphocyte biology and disease.","volume":"38","author":"Davis","year":"2014","journal-title":"Curr Top Microbiol Immunol"},{"key":"20","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1093\/intimm\/dxl069","article-title":"Expression pattern of the human FcRH\/IRTA receptors in normal tissue and in B-chronic lymphocytic leukemia.","volume":"1","author":"Ebens","year":"2006","journal-title":"Int Immunol"},{"key":"21","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/0-387-46530-8_14","article-title":"Fc receptor-like proteins (FCRL): immunomodulators of B cell function.","volume":"59","author":"Cooper","year":"2007","journal-title":"Adv Exp Med Biol"},{"key":"22","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/sj.gene.6364185","article-title":"A new Fc receptor homolog, FREB2, found in germinal center B cells.","volume":"6","author":"Colonna","year":"2005","journal-title":"Genes Immun"},{"key":"23","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.cellimm.2010.08.007","article-title":"Defining the immunological phenotype of Fc receptor-like B (FCRLB) deficient mice: Confounding role of the inhibitory Fc\u03b3RIIb.","volume":"26","author":"Burrows","year":"2010","journal-title":"Cell Immunol"},{"key":"24","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.ygeno.2004.10.017","article-title":"Cloning and characterization of the human FCRL2 gene.","volume":"8","author":"Taranin","year":"2005","journal-title":"Genomics"},{"key":"25","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12943-015-0321-5","article-title":"Apoptosis, autophagy, necroptosis, and cancer metastasis.","volume":"1","author":"Yu","year":"2015","journal-title":"Mol Cancer"},{"key":"26","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.semcancer.2014.05.002","article-title":"Targeting apoptosis for anticancer therapy.","volume":"3","author":"Fulda","year":"2015","journal-title":"Semin Cancer Biol"},{"key":"27","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.tcb.2018.12.001","article-title":"EMT Transition States during Tumor Progression and Metastasis.","volume":"2","author":"Blanpain","year":"2019","journal-title":"Trends Cell Biol"},{"key":"28","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.3390\/cells8101123","article-title":"Estrogen-Receptor Expression and Function in Female Reproductive Disease.","volume":"8","author":"Yu","year":"2019","journal-title":"Cells"},{"key":"29","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1001\/jama.2018.19323","article-title":"Breast Cancer Treatment: A Review.","volume":"32","author":"Winer","year":"2019","journal-title":"JAMA"},{"key":"30","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.3390\/ijms23031242","article-title":"Estrogen Receptors-Mediated Apoptosis in Hormone-Dependent Cancers.","volume":"2","author":"Pezzi","year":"2022","journal-title":"Int J Mol Sci"},{"key":"31","doi-asserted-by":"publisher","first-page":"2983","DOI":"10.1016\/j.apsb.2021.01.003","article-title":"Alterations of DNA damage response pathway: Biomarker and therapeutic strategy for cancer immunotherapy.","volume":"1","author":"Zhou","year":"2021","journal-title":"Acta Pharm Sin B"},{"key":"32","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12943-021-01316-8","article-title":"The cancer metabolic reprogramming and immune response.","volume":"2","author":"Su","year":"2021","journal-title":"Mol Cancer"},{"key":"33","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.cell.2020.03.001","article-title":"The Emerging Landscape of Immune Cell Therapies.","volume":"18","author":"Mackall","year":"2020","journal-title":"Cell"},{"key":"34","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/nrc.2017.121","article-title":"Targeting B cell receptor signalling in cancer: preclinical and clinical advances.","volume":"1","author":"Wiestner","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"35","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/s41577-020-00410-0","article-title":"The role of IgG Fc receptors in antibody-dependent enhancement.","volume":"2","author":"Ravetch","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"36","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s43018-020-00136-x","article-title":"Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunity.","volume":"2","author":"Nguyen","year":"2021","journal-title":"Nat Cancer"},{"key":"37","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1038\/s43018-022-00447-1","article-title":"Anti-CTLA-4 antibodies drive myeloid activation and reprogram the tumor microenvironment through Fc\u03b3R engagement and type I interferon signaling.","volume":"3","author":"Amit","year":"2022","journal-title":"Nat Cancer"},{"key":"38","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.biocel.2006.10.018","article-title":"Ntal\/Lab\/Lat2.","volume":"3","author":"Gilfillan","year":"2007","journal-title":"Int J Biochem Cell Biol"},{"key":"39","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/ni882","article-title":"LAB: a new membrane-associated adaptor molecule in B cell activation.","volume":"4","author":"Zhang","year":"2003","journal-title":"Nat Immunol"},{"key":"40","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.coi.2004.03.001","article-title":"Adaptors and linkers in T and B cells.","volume":"1","author":"Schraven","year":"2004","journal-title":"Curr Opin Immunol"},{"key":"41","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/s0065-2776(08)60908-6","article-title":"The role of complement in B cell activation and tolerance.","volume":"7","author":"Carroll","year":"2000","journal-title":"Adv Immunol"},{"key":"42","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/cei.12952","article-title":"Production of complement components by cells of the immune system.","volume":"18","author":"Trouw","year":"2017","journal-title":"Clin Exp Immunol"},{"key":"43","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s00281-017-0644-y","article-title":"Complement as a regulator of adaptive immunity.","volume":"4","author":"Astier","year":"2018","journal-title":"Semin Immunopathol"},{"key":"44","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1034\/j.1600-065x.2000.00605.x","article-title":"Regulation of the phospholipase C-gamma2 pathway in B cells.","volume":"17","author":"Takata","year":"2000","journal-title":"Immunol Rev"},{"key":"45","doi-asserted-by":"publisher","first-page":"3985","DOI":"10.1182\/blood-2007-05-088468","article-title":"Extracellular calcium sensing promotes human B-cell activation and function.","volume":"11","author":"Spaner","year":"2007","journal-title":"Blood"},{"key":"46","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.it.2006.12.007","article-title":"Antigen receptor signalling: a distinctive role for the p110delta isoform of PI3K.","volume":"2","author":"Vanhaesebroeck","year":"2007","journal-title":"Trends Immunol"},{"key":"47","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/s0960-9822(00)00358-4","article-title":"PDGF initiates two distinct phases of protein kinase C activity that make unequal contributions to the G0 to S transition.","volume":"1","author":"Kazlauskas","year":"2000","journal-title":"Curr Biol"},{"key":"48","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1034\/j.1600-065x.2000.00611.x","article-title":"Regulation of B-cell activation and differentiation by the phosphatidylinositol 3-kinase and phospholipase Cgamma pathway.","volume":"17","author":"Clark","year":"2000","journal-title":"Immunol Rev"},{"key":"49","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1517\/14728222.2014.888416","article-title":"Newer targets for modulation of intraocular pressure: focus on adenosine receptor signaling pathways.","volume":"1","author":"Agarwal","year":"2014","journal-title":"Expert Opin Ther Targets"},{"key":"50","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1172\/JCI90962","article-title":"The role of the complement system in cancer.","volume":"12","author":"Afshar-Kharghan","year":"2017","journal-title":"J Clin Invest"},{"key":"51","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1038\/s41568-019-0210-0","article-title":"Context-dependent roles of complement in cancer.","volume":"1","author":"Fridman","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"52","doi-asserted-by":"publisher","first-page":"107753","DOI":"10.1016\/j.pharmthera.2020.107753","article-title":"Tumor microenvironment as a therapeutic target in cancer.","volume":"22","author":"Yu","year":"2021","journal-title":"Pharmacol Ther"},{"key":"53","doi-asserted-by":"publisher","first-page":"a026781","DOI":"10.1101\/cshperspect.a026781","article-title":"Tumor Microenvironment and Differential Responses to Therapy.","volume":"7","author":"Sahai","year":"2017","journal-title":"Cold Spring Harb Perspect Med"},{"key":"54","doi-asserted-by":"publisher","first-page":"110873","DOI":"10.1016\/j.biopha.2020.110873","article-title":"Tumor-infiltrating lymphocytes: Warriors fight against tumors powerfully.","volume":"13","author":"Li","year":"2020","journal-title":"Biomed Pharmacother"},{"key":"55","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ctrv.2018.12.001","article-title":"B cell and B cell-related pathways for novel cancer treatments.","volume":"7","author":"Lenz","year":"2019","journal-title":"Cancer Treat Rev"},{"key":"56","doi-asserted-by":"publisher","first-page":"eabf9419","DOI":"10.1126\/science.abf9419","article-title":"Tertiary lymphoid structures in cancer.","volume":"37","author":"Thommen","year":"2022","journal-title":"Science"},{"key":"57","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/nri3469","article-title":"How B cells capture, process and present antigens: a crucial role for cell polarity.","volume":"1","author":"Lennon-Dum\u00e9nil","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"58","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.4049\/jimmunol.180.3.1362","article-title":"Helper B cells promote cytotoxic T cell survival and proliferation independently of antigen presentation through CD27\/CD70 interactions.","volume":"18","author":"Marincola","year":"2008","journal-title":"J Immunol"},{"key":"59","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/s41568-021-00339-z","article-title":"Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion.","volume":"2","author":"Delamarre","year":"2021","journal-title":"Nat Rev Cancer"},{"key":"60","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s00018-017-2686-7","article-title":"CD4 and CD8 T lymphocyte interplay in controlling tumor growth.","volume":"7","author":"Woller","year":"2018","journal-title":"Cell Mol Life Sci"},{"key":"61","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/bs.ircmb.2018.05.010","article-title":"T Lymphocyte-Based Cancer Immunotherapeutics.","volume":"34","author":"Maleki Vareki","year":"2018","journal-title":"Int Rev Cell Mol Biol"},{"key":"62","doi-asserted-by":"publisher","first-page":"e000966","DOI":"10.1136\/jitc-2020-000966","article-title":"T-cell agonists in cancer immunotherapy.","volume":"8","author":"Hajjar","year":"2020","journal-title":"J Immunother Cancer"},{"key":"63","doi-asserted-by":"publisher","first-page":"e463","DOI":"10.1016\/S1470-2045(20)30328-4","article-title":"Treatment after progression in the era of immunotherapy.","volume":"2","author":"Gil","year":"2020","journal-title":"Lancet Oncol"},{"key":"64","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/s41392-022-01136-2","article-title":"Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response.","volume":"7","author":"Sun","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"65","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13046-021-02215-y","article-title":"The CD70-CD27 axis in oncology: the new kids on the block.","volume":"4","author":"Jacobs","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"66","doi-asserted-by":"publisher","first-page":"e000629","DOI":"10.1136\/esmoopen-2019-000629","article-title":"New emerging targets in cancer immunotherapy: CD27 (TNFRSF7).","volume":"4","author":"Berghoff","year":"2020","journal-title":"ESMO Open"},{"key":"67","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/s41591-021-01245-5","article-title":"Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma.","volume":"2","author":"Goebeler","year":"2021","journal-title":"Nat Med"},{"key":"68","doi-asserted-by":"publisher","first-page":"e002787","DOI":"10.1136\/jitc-2021-002787","article-title":"GDF15 induces immunosuppression via CD48 on regulatory T cells in hepatocellular carcinoma.","volume":"9","author":"Zhang","year":"2021","journal-title":"J Immunother Cancer"},{"key":"69","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.cytogfr.2022.06.004","article-title":"The IL-2A receptor pathway and its role in lymphocyte differentiation and function.","volume":"6","author":"Zhao","year":"2022","journal-title":"Cytokine Growth Factor Rev"},{"key":"70","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/s41423-020-00599-z","article-title":"Efficient IL-2R signaling differentially affects the stability, function, and composition of the regulatory T-cell pool.","volume":"1","author":"F\u00f6rster","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"71","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.semcancer.2022.03.014","article-title":"Immune checkpoint proteins: Signaling mechanisms and molecular interactions in cancer immunotherapy.","volume":"8","author":"Srivastava","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"72","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s12943-019-1091-2","article-title":"Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4.","volume":"1","author":"Luo","year":"2019","journal-title":"Mol Cancer"},{"key":"73","doi-asserted-by":"publisher","first-page":"e000957","DOI":"10.1136\/jitc-2020-000957","article-title":"TIGIT in cancer immunotherapy.","volume":"8","author":"Zarour","year":"2020","journal-title":"J Immunother Cancer"},{"key":"74","doi-asserted-by":"publisher","first-page":"118110","DOI":"10.1016\/j.lfs.2020.118110","article-title":"Immune escape: A critical hallmark in solid tumors.","volume":"25","author":"Mortezaee","year":"2020","journal-title":"Life Sci"},{"key":"75","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/j.molcel.2020.02.013","article-title":"PD-1: A Driver or Passenger of T Cell Exhaustion?","volume":"7","author":"Xu","year":"2020","journal-title":"Mol Cell"},{"key":"76","doi-asserted-by":"publisher","first-page":"654960","DOI":"10.3389\/fimmu.2021.654960","article-title":"Roles of BTLA in Immunity and Immune Disorders.","volume":"1","author":"Xiong","year":"2021","journal-title":"Front Immunol"},{"key":"77","doi-asserted-by":"publisher","first-page":"100796","DOI":"10.1016\/j.drup.2021.100796","article-title":"Anticancer drug resistance: An update and perspective.","volume":"5","author":"Jang","year":"2021","journal-title":"Drug Resist Updat"},{"key":"78","doi-asserted-by":"publisher","first-page":"bbac558","DOI":"10.1093\/bib\/bbac558","article-title":"GSCA: an integrated platform for gene set cancer analysis at genomic, pharmacogenomic and immunogenomic levels.","volume":"2","author":"Guo","year":"2023","journal-title":"Brief Bioinform"}],"container-title":["Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.aging-us.com\/lookup\/doi\/10.18632\/aging.204766","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T21:58:16Z","timestamp":1685743096000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aging-us.com\/lookup\/doi\/10.18632\/aging.204766"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,2]]},"references-count":78,"alternative-id":["204766"],"URL":"https:\/\/doi.org\/10.18632\/aging.204766","relation":{},"ISSN":["1945-4589"],"issn-type":[{"value":"1945-4589","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,2]]}}}